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Although infections with virulent pathogens often in-
duce a strong inflammatory reaction, what drives the
increased immune response to pathogens compared
to nonpathogenic microbes is poorly understood.
One possibility is that the immune system senses
the level of threat from a microorganism and aug-
ments the response accordingly. Here, focusing on
cytotoxic necrotizing factor 1 (CNF1), an Escherichia
coli-derived effector molecule, we showed the host
indirectly sensed the pathogen by monitoring for
the effector that modified RhoGTPases. CNF1 modi-
fied Rac2, which then interacted with the innate
immune adaptors IMD and Rip1-Rip2 in flies and
mammalian cells, respectively, to drive an immune
response. This response was protective and in-
creased the ability of the host to restrict pathogen
growth, thus defining a mechanism of effector-trig-
gered immunity that contributes to how metazoans
defend against microbes with pathogenic potential.
INTRODUCTION
Although infections with virulent pathogens are often associated
with a strong inflammatory reaction, what drives this increased
immune response to pathogens but not commensals is poorly
understood. The heightened immune response is often consid-
ered to be an epiphenomenon of the increased bacterial load
or to be required for the virulence of the invading microbe. An
alternative, more host-centric view is that the immune system
may be able to sense the level of threat from a microorganism
and augment the defense reaction accordingly. However, how
virulence is recognized at a molecular level and what strategies
contribute to fine-tune the innate immune response after536 Immunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc.infection with micro-organisms that have pathogenic potential
remains poorly understood.What is clear is that models of innate
immunity focused on pattern recognition receptors (PRRs) that
recognize invariant molecules encoded by microbes (Akira
et al., 2001) cannot adequately explain how we discriminate
between avirulent and virulent micro-organisms as the microbial
associated molecular patterns (MAMPs) that are recognized are
often intrinsic to all bacteria (Iwasaki and Medzhitov, 2010;
Medzhitov, 2010; Vance et al., 2009).
One defining characteristic of pathogenic bacteria is the
expression of virulence factors, also called ‘‘effectors.’’ These
bacterial proteins enter host cells and manipulate host compo-
nents to promote infection (Gala´n, 2009; Ribet and Cossart,
2010). One potential strategy for pathogen discrimination is
that the host monitors for effectors that are specifically encoded
by virulent bacteria and uses this information to gauge the path-
ogenic potential of the invading organisms. Work in plants has
shown this to be the case and, in addition to PRR-based recog-
nition, plants have sophisticated systems of effector-triggered
immunity (ETI) based on the direct or indirect recognition of
microbial-encoded effectors (Jones and Dangl, 2006). Impor-
tantly, this effector-triggered immunity is a powerful means of
augmenting the defense response specifically to pathogens
but not harmless commensals and makes a significant contribu-
tion to how plants restrict pathogen growth. However, although
attractive as a strategy of immune surveillance, evidence of
how effector-triggered immunity contributes to defense in meta-
zoans is lacking.
A common virulence strategy used by pathogens is to express
effectors that target the master regulators of the cytoskeleton,
the RhoGTPases (Aktories et al., 2000; Lemonnier et al., 2007).
These important proteins are targeted by pathogens because
they participate in a number of innate immune processes
(Bokoch, 2005). Cytotoxic necrotizing factor 1 (CNF1), produced
by uropathogenic Escherichia coli (UPEC), is a prototype of the
RhoGTPases-activating toxins (Flatau et al., 1997; Lerm et al.,
1999; Schmidt et al., 1997). CNF1 secreted by UPECs is internal-
ized via receptor-mediated endocytosis before translocating
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modifies RhoGTPases (Lemonnier et al., 2007). Here, we refer
to CNF1 as an ‘‘effector’’ because it shares with toxins intro-
duced into the cytosol by protein secretion systems (Gala´n,
2009) both an intracellular site of action and the ability to induce
posttranslational modifications of host proteins. Bacteria ex-
pressing CNF1 (and the related toxins CNFy from Yersinia
pseudotuberculosis and dermonecrotic toxin [DNT] from
Bordetella) provoke florid inflammation, leading to the sugges-
tion that CNF1 might directly contribute to immune activation.
Although previous studies have shown that purified recombinant
CNF1 can induce NF-kB activation and cytokine secretion
(Munro et al., 2004; Real et al., 2007), the molecular mechanisms
that drive the inflammatory response associated with bacteria
expressing CNF1 is poorly understood. Similarly, the conse-
quences that this has for both host and pathogen remain to be
fully defined.
In Drosophila, two well-defined immune signaling cascades,
the Toll and IMD pathways, regulate secretion of a number of
antimicrobial peptides (AMPs) such as Drosomycin, acting
predominantly downstream of Toll, and Diptericin, being pro-
duced as a consequence of IMD activation (Ferrandon et al.,
2007; Lemaitre and Hoffmann, 2007). The evolutionarily conser-
vation with mammals has made Drosophila is a useful model for
studies of pathogenesis. Interestingly, the insect-pathogenic
bacterium Photorhabdus luminescens expresses an effector
called Pnf with sequence similarity to the catalytic domain of
CNF1 (Waterfield et al., 2002), suggesting that Drosophila might
be an appropriate model host in which to study the conse-
quences of this type of effector on host immunity. Here, we
have taken advantage of tractability of flies to demonstrate
the intrinsic immunostimulatory capacity of CNF1 in vitro and
in vivo. We found that CNF1 was sufficient for inducing an
immune response in the absence of other microbial-derived
innate immune agonists. This immune response was not simply
a bystander of the virulence activity of CNF1 but was protective
and conferred upon the host an increased resistance to infection
with both CNF1-expressing E. coli and other pathogenic strains.
The immune response to CNF1 was initiated not by direct
recognition, but indirectly, in response to modification and
activation of a host protein, the RhoGTPase Rac2. Modified
Rac2 then engaged immune signaling pathways via the innate
immune adaptor IMD. Extending these observations to mam-
mals, we showed that this immune response to CNF1 was
conserved and triggered by the engagement of Rip proteins after
human Rac2 activation. These data defined a mechanism by
which the immune system can sense a pathogen not through
direct recognition of MAMPs by PRRs but indirectly by sensing
the activity of microbial-derived effectors. Importantly, the
responses to such effectors can be sufficient to drive protective
immunity and help the metazoan host resist microbes with path-
ogenic potential.
RESULTS
CNF1 Induces an Effector-Triggered Immune Response
that Contributes to Host Resistance
To test whether CNF1 directly causes immune activation and
if the immunostimulatory capacity was conserved in flies, weexpressed CNF1 in Drosophila S2 cells and determined the
amounts of induced AMPs. Consistent with an intrinsic immu-
nostimulatory capacity, expression of CNF1 in S2 cells induced
transcriptional upregulation of AMPs (Figure 1A). The immunos-
timulation required the catalytic activity given that expression of
the inactive point mutant, CNF1C866S, did not induce AMPs in
Drosophila S2 cells. To test whether there was immunostimula-
tory capacity in vivo, we injected Drosomycin-GFP reporter flies
(Ferrandon et al., 1998) with purified CNF1 or CNF1C866S and
assayed the induction of GFP as a surrogate of AMP expression
(Figure 1B). Injection of CNF1, but not the catalytically inactive
mutant toxin, was associated with induction of AMPs, suggest-
ing that the immunostimulatory capacity of CNF1 occurred
in vivo. We further generated transgenic flies expressing either
the carboxy-terminus catalytically active CNF1 (CNF1CT) or the
catalytically inactive point mutant (CNF1CS) under the control
of upstream activating sequences (UASs), allowing us to control
expression by the coexpression of GAL4. To test whether the
effector would be associated with immunostimulation in vivo,
we generated flies in which CNF1 could be ubiquitously ex-
pressed under the control of a temperature-sensitive and induc-
ible promoter (HSP70-GAL4; Tubulin-GAL80ts). Similar to our
in vitro observations, induction of CNF1CT expression, but not
the inactive, CNF1CS, was sufficient for inducing AMP expres-
sion in vivo (Figure 1C). Together, these data indicate that
CNF1 has intrinsic immunostimulatory capacity and was suffi-
cient for inducing an effector-triggered immune response both
in vitro and in vivo.
To determine the in vivo consequences of this effector-trig-
gered immune response, we next infected flies with J96 UPEC
strain or J96-DCNF1 by septic injury and then monitored the
persistence of the bacteria in vivo. Expression of CNF1 resulted
in rapid eradication of the WT parent strain (J96), whereas dele-
tion of this effector allowed J96-DCNF1 bacteria to persist in the
host (Figure 1D). Thus, expression of CNF1 appeared to favor the
host by increasing the ability to eradicate infections with E. coli
J96. Pseudomonas aeruginosa PA14 is highly virulent, rapidly
killing WT flies within hours of septic injury. To test whether the
effector-triggered response induced by CNF1 could be protec-
tive against a highly virulent microbe, we used flies expressing
UAS-CNF1CT, or the control UAS-CNF1CS, and infected them
with Pseudomonas by septic injury (Figure 1E). Control flies
died rapidly, reaching 50% mortality by 15 hr. In contrast,
UAS-CNF1CT flies showed increased survival, with only 10%
death at the same time point and reaching 50% mortality after
30 hr. Thus, CNF1 can function as an ‘‘avirulence’’ factor
because its expression drives a protective immune response
and increases the ability of the resistant host to clear infections.
CNF1 Modifies the Rho-GTPase Rac2, which Induces
a Defense Response
Both heat inactivation and mutation of the catalytic site
destroyed the immunostimulatory capacity of CNF1, indicating
that the enzymatic activity of CNF1 was required for induction
of the Drosophila immune response. In mammals, CNF1 cata-
lyzes a deamidation of the glutamine 63 of Rho or the equivalent
61 of Rac and Cdc42 into a glutamic acid (Flatau et al., 1997;
Lerm et al., 1999; Schmidt et al., 1997). This modification abol-
ishes the GTPase activity of the Rho proteins, locking them inImmunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc. 537
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Figure 1. E. coli-Derived CNF1 Induces Effector-Triggered Immunity in the Absence of Other Bacterial Components and Contributes to Host
Resistance In Vivo
(A) In vitro induction of Drosomycin (black bars) and Diptericin (white bars) after transfection of catalytically active C terminus of CNF1 (CNF1CT) and the inactive
point mutant (CNF1CS) in Drosophila S2 cells. AMPs were monitored by QRT-PCR and normalized to RP49 (mean ± SD). The insert shows equivalent protein
expression of WT and mutant toxin C-termini.
(B) In vivo induction of Drosomycin-GFP in reporter flies injected with purified CNF1 (105 M) or inactive point mutant C866S (CNF1C866S) control toxin. Data
expressed as integrated total GFP fluorescence per fly.
(C) In vivo induction of AMPs of by heat shock (HS) in flies expressing UAS-GFP or the catalytically active C terminus of CNF1 (CNF1CT) and inactive point mutant
(CNF1CS) under the control of an HSP70-Gal4, tubulin-Gal80ts inducible driver. Data representative of mean ± SD of individual flies in one experiment and
representative of experiments using three or more independent CNF1CT or CNF1CS transgenic insertion lines.
(D) In vivo bacterial loads in OR flies infected with E. coli J96 (black) or mutants lacking CNF1 (gray) at the indicated times. Mean ± range of c.f.u. per fly calculated
at two different dilutions. Data are representative of more than three similar experiments.
(E) In vivo survival of CNF1CT or control CNF1CS flies infected with Pseudomonas PA14. *p < 0.05, **p < 0.01.
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whether similar CNF1-mediated modification of Rho proteins
occurred in flies and was involved in immune activation. Ectopic
expression of RhoGTPase in theDrosophila eye has been shown
to cause characteristic changes in the ommatidia (Raymond
et al., 2001). To confirm that CNF1 was active in flies and to
determine which RhoGTPase was likely to be the major in vivo
target, we expressed CNF1 in the eye with the GMR-GAL4
driver. Expression of the catalytically active CNF1CT, but not
the inactive point mutant CNF1CS, during development was
associated with marked disruption of ommatidia and a severe
rough eye phenotype, confirming the functionality of this toxin
in vivo (Figure 2A). Although overexpression-induced eye pheno-
types often rely on pleiotropic effects, the phenotype of the
GMR-Gal4 > UAS-CNF1 flies most closely resembled Rac over-
expression, and was distinct from the phenotypes observed
after overexpressing of Rho or Cdc42 (Raymond et al., 2001),
suggesting that Rac was likely to be the major in vivo target of
this effector. To directly test whether the immune response trig-
gered byCNF1might bemediated by Rac2, we intoxicated Rac2
deficient (Rac2D) flies by using purified CNF1. AMP expression
was abrogated in Rac2D flies (Figure 2B), indicating that Rac2538 Immunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc.played a nonredundant role in triggering the immune response
to this effector. Further suggesting a potential role for Rac2,
both J96 and J96-DCNF1 showed comparable growth in flies
lacking Rac2 (Rac2D) (Figure S1A), an observation that was in
keeping with the possibility that the immune response triggered
by CNF1 was mediated by Rac2. However, consistent with
previous reports (Avet-Rochex et al., 2007), and independent
of CNF1, Rac2D flies showed increased susceptibility to infec-
tion with J96 (Figure S1B) and other pathogens and somewhat
confounded interpretation of these data.
To confirm that Drosophila Rac2 could be modified by the
catalytic activity of CNF1, we exposed GST-purified Rac2 to
CNF1 in a cell-free system and assessed the ability of the toxin
to modify Rac2 by mass spectrometry (Figures 2C and 2D).
Purified toxin was sufficient for inducing a posttranslational
modification of the glutamine at amino acid 61 in Drosophila
Rac2 (Figure 2D), demonstrating that the activity of this effector
was conserved across species and suggesting Rac2 as a likely
in vivo target. Because mutating amino acid 61 of mammalian
Rac results in activation, we next tested whether activating
mutants of Drosophila Rac2 were associated with AMP induc-
tion. Similar to mammalian RhoGTPase, modifying glutamine
Immunity
Effector-Triggered Immunity via Rac2 and IMD61 of Drosophila Rac2 by genetically mutating it to leucine
(Rac2L61) was associated with marked cytoskeletal changes
and prominent lamellipodia formation (Figure S1C), confirming
that modifying this amino acid also resulted in an activating
mutant in flies. Expression of Rac2L61, but not the inactive
Rac2 mutant (Rac2N17), was sufficient for inducing AMP expres-
sion in S2 cells and hence recapitulated the effects of CNF1
(Figure 2E). Similar results were seen when two other activating
mutants of Rac2 were expressed: the Rac2E61 mutant, mimick-
ing the exact modification induced by CNF1, and Rac2V12 (Fig-
ure 2F). Although not as potent as activation of the two innate
immune pathways by expression of the receptors Toll10b or
PGRP-LC, Rac2L61 induced AMPs to levels 25%–30% of these
well-studied immune triggers (Figure 2G). Similar to our in vivo
observations using CNF1CT transgenic flies (Figure 1C), AMP
expression was also upregulated in flies when Rac2L61, but not
the inactive mutant, was inducibly expressed in vivo using
a heat shock driver (Figure 2H). Together, these data indicate
that activation of Rac2 is both necessary and sufficient for
CNF1 to induce AMP expression.
CNF1-Mediated Immunostimulation Is Not Due
to Cytoskeletal Disruption
Both Rac2L61 (Figure S1) and CNF1 (Figure S2) expression are
associated with marked cytoskeletal changes and prominent
lamellipodia formation. Upon activation of RhoGTPase, confor-
mational changes occur in two conserved nucleotide contact
regions, switch 1 and switch 2, to allow interaction with the
different effector proteins that regulate different downstream
signals including cytoskeletal rearrangement. To determine
whether the effects seen by expression of Rac2L61 was simply
due to disruption of the actin cytoskeleton, we generated
effector loop mutants of activated Rac2L61 and used them
to test whether the elicited cytoskeletal changes could be disso-
ciated from the induction of AMPs. Introduction of a F37A muta-
tion into the Rac2L61 blocked lamellipodia formation (Figure 3A),
whereas introduction of a Y40Cmutation did not affect the regu-
lation of the cytoskeleton (Figure 3A) but disrupted binding to
GST-Pak (Figure S2). Similar to Rac2L61, transient transfection
of Rac2L61,A37 induced AMP expression. This contrasted with
expression of Rac2L61,C40, which was not associated with induc-
tion of AMPs (Figure 3B) despite causing prominent cytoskeletal
changes. In addition, Rac2L61 had to be able to associate with
membranes given that the Rac2L61, Delta-CAAX, in which the
membrane insertion tail had been deleted, was not able to
induce AMPs (Figure 3C). Thus, signaling to the immune system
requires membrane targeting of Rac2 and is regulated through
the switch 1 effector-binding domain, providing mechanistic
insights into how Rac2 intersects immune signaling pathways.
Additionally, these data indicate that Rac2L61 induced a defense
response in the absence of other microbial components and
independently of its ability to modify of the cytoskeleton.
Rac2 Induces Activation of Defense Pathways through
an IMD-Dependent Mechanism
Because Rac2L61 mimicked the molecular changes induced by
CNF1, this mutant was used to probe the signaling pathways
leading to AMP expression after exposure to this toxin. Given
that disruption of the cytoskeleton did not appear to be essentialfor Rac2L61 to induce AMP expression, we instead determined
whether this occurred through any of the known defense path-
ways in flies. Rac2L61 inducedDrosomycin expression (Figure 2),
leading us to test whether Rac2L61 activated Dorsal, the NF-kB-
like molecule that can regulate this AMP. For Dorsal activation,
Cactus, an I-kB-like molecule that acts as an inhibitor of Dorsal
by retaining it in the cytoplasm, must be phosphorylated and
targeted for proteasomal degradation (Wu and Anderson,
1998). Consistent with Rac2L61-induced degradation of Cactus,
increasing the expression of Rac2L61 inversely correlated with
the amounts of endogenous Cactus detected (Figure 4A). Corre-
lating with this decrease in Cactus, nuclear localization of GFP-
Dorsal occurred in >95% of cells cotransfected with the active
Rac2L61, but only 40% with the inactive Rac2N17 mutant (Fig-
ure 4B). Because Rac2L61 also inducedDiptericin, we next deter-
mined whether it also activated Relish, the NF-kB transcription
factor regulating this gene. Activation of Relish (as determined
by phosphorylation and cleavage (Ertu¨rk-Hasdemir et al., 2009)
was detectable when cells expressed Rac2L61 (and the positive
control, PGRP-LC) but not Rac2N17 (or the negative control
Toll10b) (Figure 4C). Additionally, nuclear translocation of YFP-
Relish occurred in >90% of cells cotransfected with the active
Rac2 but only 30% cotransfected with the inactive Rac2 mutant
(Figure 4D). Thus, Rac2L61 was sufficient to activate two of
the important innate immune transcription factors, Dorsal and
Relish.
To further define the innate immune signaling pathway trig-
gered by Rac2L61, we performed an RNAi epistasis screen in
which the components of Toll, IMD, and JNK pathways were
silenced and their requirement for AMP induction by Rac2L61
determined (Figure S3). Knockdown of all genes in the IMD
pathway inhibited Rac2L61-induced AMP expression (Figure 4E).
Conversely, silencing of the majority of the Toll pathway compo-
nents did not decrease theAMP induction byRac2L61 (Figure 4E).
The third innate immune pathway in flies, the JNK pathway,
was not required for Rac2L61-induced AMP expression because
RNAi silencing neitherBasket norHemipterous affectedRac2L61-
induced AMP expression (Figure 4E). Together these data
suggest that Rac2 activates an innate immune response that
had potential to regulate both Diptericin and Drosomycin and
utilizes signaling components primarily from the IMD pathway.
Modified Rac2 Interacts with IMD to Induce an Immune
Response
Because IMD was the most apical component of the pathway
induced by Rac2L61 expression, we next tested whether IMD
interacted with Rac2. To determine whether these proteins colo-
calized, we transiently expressed mRFP-Rac2L61 or mRFP-
Rac2N17 in S2 cells and determined their relationship to endog-
enous IMD by microscopy. IMD was detected predominantly in
the nucleus both in resting cells (data not shown) and in the pres-
ence ofmRFP-Rac2N17 (whichwas found primarily in the cytosol)
(Figure 5A). In contrast, when mRFP-Rac2L61 was expressed,
a proportion of IMD redistributed and was found in membrane
ruffles and in the perinuclear region along with Rac2L61 (Fig-
ure 5A). A similar redistribution of Flag-IMD was also observed
when ectopically expressed with Rac2L61 but not Rac2N17 (Fig-
ure S4). To confirm the association of IMD and Rac2, we used
S2 cells stably expressing Rac2L61, Rac2N17, or LacZ fusedImmunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc. 539
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Figure 2. CNF1 Modifies the Small RhoGTPase, Rac2, which Induces a Defense Response
(A) Absence of the ommatidia and a severe rough eye phenotype due to ectopic expression of the toxin in GMR-Gal4/UAS-CNF1CT flies but not control or GMR-
Gal4/UAS-CNF1CS flies.
(B) In vivo intoxication of WT (black bars) or Rac2D (white bars) flies with purified CNF1 toxin and AMPs measured at 6 hr. Drosomycin and Diptericin expression
profiles were quantified by QRT-PCR in pools of three or more flies (mean ± SEM of six pools from three independent experiments).
(C and D)Mass spectrometry chromatograms of (C) native GST-Rac2 and (D) CNF1-modifiedGST-Rac2. The upper panel represents the total ion chromatogram
of GST-Rac2 before (C) or after (D) CNF1 modification. Lower panels show the extracted ion chromatogram for the peptide that includes the position 61 of Rac2
targeted by CNF1 before (C) or after (D) CNF1 modification. The predicted protein sequences are shown.
(E) In vitro expression of Diptericin, Drosomycin,Metchnikowin, AttacinA, and CecropinA in S2 cells 16 hr after transfection with Flag-Rac2, Flag-Rac2L61, Flag-
Rac2N17, or Flag plasmid (control). AMPs were monitored with QRT-PCR, normalized to RP49, and expressed relative to the empty flag construct (mean ± SD).
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Effector-Triggered Immunity via Rac2 and IMDto a Bioease tag that allowed intracellular biotinylation of
these proteins. IMD was detected in total cell lysates from
these three cell lines (Figure 5B). After pull-down of the bio-
tinylated proteins, IMD was found to interact with Rac2L61 but
not Rac2N17 or LacZ (Figure 5B). Thus, IMD associated bio-
chemically and colocalized by fluorescent microscopy with
active Rac2. Using a similar approach, we were unable to show
any interaction of Rac2L61 with Myd88 (data not shown). The
ability of activated Rac2 to bind IMD suggested that CNF1-modi-
fied Rac2 might also bind IMD. To test the possibility that this
interaction was involved in the induction of AMPs by CNF1, we
determined whether Rac2 that had been exposed to CNF1 in
a cell-free system had increased affinity for IMD. In GST pull-
down assays, native WT Rac2 showed minimal association
with IMD whereas Rac2 modified by the toxin CNF1 efficiently
bound IMD from cell lysates (Figure 5C). Thus, both genetically
and toxin-modified Rac2 interact with the innate immune
adaptor, IMD.
We next determined whether IMD was required for CNF1 to
induce AMPs in vivo by using two different IMD mutants, imd1,
a hypomorphic allele, and imdshadok, a null allele. Flies were
intoxicated with CNF1 and AMPs were determined. Similar to
the Rac2D mutant flies (Figure 2B), imd1 and imdshadok flies
both showed reduced AMP induction after CNF1 exposure (Fig-
ure 5D). Consistent with our in vitro observations using RNAi,
Myd88 flies showed a partial defect in induction of AMPs after
CNF1 intoxication. Notably, theMyd88 flies were not as impaired
as the imdshadok flies supporting the notion that IMDwas the prin-
ciple adaptor required for this pathway. To confirm that the
avirulence activity of CNF1 was indeed propagated by Rac2
and IMD, we infected flies with J96 or J96-DCNF1 E. coli and
monitored bacterial persistence. Unlike WT flies, which effi-
ciently cleared the J96 strain but not the J96-DCNF1 E. coli (Fig-
ure 1 and Figure 5F), flies that lacked either Rac2 or IMD were
unable to clear either strain, confirming that the avirulence
activity required both Rac2 and IMD (Figure 5F and Figure S1).
Together, these data indicate that CNF1 modification of Rac2
and its subsequent interaction with IMD drives the effector-trig-
gered immune response that occurs with this toxin and is
required for its avirulence activity.
Finally, we set out to test whether CNF1 was sufficient to
trigger a protective immune response independently of the two
PRRs upstream of IMD, PGRP-LC, and PGRP-LE. Because the
virulence of J96 was problematic when doing survival experi-
ments with these compromised strains, we instead engineered
E. coli in which we could controllably express either CNF1 or
the inactive control toxin CNF1-C866S using IPTG and used
these bacteria to infect WT, imd1, or PGRP-LC and -LE
double-mutant flies (Figure 5G). imd1 flies succumbed to both
bacterial strains, whereas WT flies were resistant. In contrast,
PGRP-LC and -LE mutant flies were as susceptible as imd1
only to E. coli CNF1-C866S but were relatively resistant to(F) The upper panel represents the in vitro expression of Diptericin and Drosomy
Rac2E61, and Flag-Rac2V12. The lower panel is an immunoblot analysis showing
(G) In vitro AMP expression induced by transfection of S2 cells with Rac2L61, To
(H) In vivo induction of AMPs of by heat shock (HS) in flies expressing UAS-GFP
HSP70-Gal4, tubulin-Gal80ts inducible driver. Data represent the mean ± SEM o
representative of results using three or more independent Rac2L61 or Rac2N17 trE. coli-CNF1. These data are consistent with CNF-1 being suffi-
cient for rescuing the susceptibility of the PGRP-LC and -LE
mutants by promoting resistance through a PRR-independent,
effector-triggered mechanism that relies on IMD.
Human Rac2 Induces Immune Activation through Rip1
and Rip2
The so-called ‘‘death’’ domains of Drosophila IMD and the
mammalian protein Rip1 are homologous. Rip1, and the related
molecule Rip2 (RICK), are important adaptor proteins for
a number of innate immune signaling pathways that function
upstream of NF-kB, IRF, and caspase-dependent effectors in
mammals (Meylan and Tschopp, 2005). We therefore investi-
gated whether, like Drosophila Rac2 and IMD, hRac2 interacted
with Rip1 and Rip2. To determine whether these proteins inter-
acted, we coexpressed Myc-tagged hRac2L61 and hRac2N17
mutants with Flag-tagged Rip1 or Rip2 in HEK293T cells.
hRac2L61, but not hRac2N17, immunoprecipitated with both
Rip1 and Rip2 (Figure 6A). To establish the cellular localization
of these interactions, we visualized the proteins by immunofluo-
rescent microscopy. Although the distribution of staining
differed, colocalization of active hRac2L61 was observed with
both Rip1 and Rip2 (Figures 6B and 6C). Rip1, which was found
in mitochondria (Figure S5), minimally colocalized with hRac2N17
(Figure 6B) but colocalized extensively with Myc-hRac2L61 in
these organelles (Figure 6B). Rip2 colocalized with Myc-
hRac2L61 in membrane ruffles (Figure 6C).
Mammalian epithelial cells do not express many classic PRRs
and are relatively resistant to microbial stimuli, a characteristic
that is thought to help them tolerate the constant exposure to
the harmless commensal microflora. However, the epithelium
also remains responsive to pathogen attack and must therefore
utilize alternative non-TLR mechanisms to sense virulent patho-
gens. Because CNF1 is expressed by E. coli J96, a causative
agent of urinary tract infection and pyelonephritis in humans,
we next set out to determine whether human kidney epithelial
cells (HEK293T cells) might also utilize this type of PRR-indepen-
dent sensing to respond to uropathogenic bacteria. Consistent
with a conserved immunostimulatory capacity and previous
reports (Munro et al., 2004), treatment of HEK293T cells with
purified CNF1, but not to heat-inactivated control toxin, was
sufficient for inducing NF-kB activation in the absence of other
microbial components (Figure 7A). The level of induction of the
immune response was comparable to that induced by 100 ng/ml
of LPS (Figure 7B). The ability of CNF1 to induce immune
responses required Rac activation given that expression of
hRac2N17, which can function as a dominant-negative inhibitor
of Rac, blocked the response (Figure 7C). Furthermore, similar to
our observations in Drosophila, expression of active hRac2L61 in
HEK293T cells, but not inactive hRac2N17, caused NF-kB activa-
tion (Figure 7D) and transcriptional upregulation of a number of
innate immune genes including IL-8, IL-1b, TNFa, and type 1cin in S2 cells 16 hr after transfection with Flag-Rac2N17, Flag-Rac2L61, Flag-
levels of expression of the Flag-Rac2 mutants.
ll10b, and PGRP-LC (mean ± SD).
or active Rac2 (Rac2L61) and inactive mutant (Rac2N17) under the control of an
f ‘‘n’’ individual flies pooled from three or more independent experiments and
ansgenic insertion lines; *p < 0.05, **p < 0.01.
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Figure 3. Rac2 Induces an Immune Response Independently of Cytoskeletal Changes
(A) Cell morphology of S2 cells expressing Flag-Rac2L61 and switch mutant, Flag-Rac2L61,C40, but not Flag-Rac2L61,A37. Large-scale image is actin (phalloidin-
FITC). Smaller images show red, anti-Flag; blue, DAPI and the merge with green, actin (phalloidin-FITC). Scale bar 10 mm.
(B) In vitro AMP expression in S2 cells expressing Flag-Rac2L61 and switch mutant, Flag-Rac2L61,A37, but not Flag-Rac2L61,C40(mean+/s.d). Insert demon-
strating equivalent expression of all constructs. (C) In vitro AMP expression induced in S2 cells by expressing Flag-Rac2L61 and the DCAAX mutant (mean ± SD).
*p < 0.05, **p < 0.01.
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Effector-Triggered Immunity via Rac2 and IMDinterferons as measured by QRT-PCR and RT2 Profiler PCR
Array (Figure 7E and Figure S6). These data indicate that
hRac2L61 had the potential to regulate NF-kB and IRF pathways
in mammalian cells and that, similar to flies, Rac2 is both neces-
sary and sufficient for the CNF1-induced immune response.
To determine whether hRac2 signaled via Rip1 and Rip2 to
induce immune activation, we treated HEK293T cells treated542 Immunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc.for 48 hr with siRNAs to Rip1, Rip2 or transfected both Rip1
and Rip2 with hRac2L61 and an NF-kB reporter construct and
induction of NF-kB measured after 24 hr. The transfection levels
and efficiency of Rip1 and Rip2 silencing by RNAi treatment was
confirmedby functional validation and immunoblotting (Figure 7F
and Figure S6). When compared to nontargeting control siRNA,
depletion of Rip1 and Rip2 resulted in a 30% and 40% inhibition
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Figure 4. Modified Rac2 Induces Activation of NF-kB-like Innate Immune Transcription Factors through an IMD-Dependent Mechanism
(A) Immunoblot of Cactus in stable S2 cell lines expressing Rac2L61. Streptavidin-HRP staining indicates levels of BioeaseRac2L61 induced by increasing
concentration of CuSO4 as indicated. Actin staining is shown as a loading control.
(B) In vitro localization of Dorsal was assayed by blind counting of cells cotransfected with GFP-Dorsal and the Flag-tagged Rac2 mutants, Rac2L61 (active) or
Rac2N17 (inactive).
(C) Immunoblot showing levels of the transcription factor Relish in S2 cells 16 hr after transient transfection with Flag-Rac2, Flag-Rac2L61, Flag-Rac2N17, Flag
empty plasmid (Ctrl), PGRP-LC, or Toll10b plasmids. Flag-tag immunostaining indicates expression of Rac2 proteins. Relish activation was determined by
detection of the 68 kDa phosphorylated, cleaved fragment. Actin staining is shown as a loading control.
(D) In vitro localization of Relish localization was assayed by blind counting of cells cotransfected with YFP-Relish and the mRFP tagged Rac2 mutants, Rac2L61
and Rac2N17.
(E) Drosomycin (black bars) and Diptericin (gray bars) expression profile were monitored in BioeaseRac2L61 stable S2 cells treated with the indicated
RNAi. BioeaseRac2L61 stable cells treated with a GFP RNAi without CuSO4 induction and induced with 500 mM CuSO4 are used as controls in each experiment.
AMPs expression was determined by QRT-PCR and normalized to the house-keeping gene RP49. Results expressed as% of the induced cells treated with GFP
RNAi, (mean ± SD) of three independent screens; *p < 0.05, Student’s t test.
Immunity
Effector-Triggered Immunity via Rac2 and IMDof Rac2-dependent NF-kB induction, respectively (Figure 7G).
Furthermore, the combination of both Rip1 and Rip2 siRNA
resulted in 60% inhibition hRac2L61-induced NF-kB activation
(Figure 7G). Similar results were observed when IL8 expression
was used as a measure of activation and quantified by QRT-
PCR (Figure 7H). Similar results were seen with a second, inde-
pendent siRNA pool (Figure S6). Thus, the two mammalian
proteins related to IMD, Rip1 and Rip2, also interact with modi-
fied Rac2 and contribute to hRac2L61-induced NF-kB activation
and IL-8 cytokine expression. Finally, to determine whether this
was the mechanism by which CNF1 induced immune activation
in mammals, we silenced Rip1 and Rip2 in HEK293T cells and
then treated them with CNF1. Paralleling our observations in
flies was the finding that CNF1 failed to induce an immune
response in the absence of Rip1 and Rip2 (Figure 7I), indicatingthat these proteins played an equivalent role as IMD in the
mammalian system. Together, these data identify an evolu-
tionary conserved mechanism of effector-triggered immunity
triggered by CNF1 modification of the RhoGTPase Rac2, and
involving the adaptor proteins IMD or Rip1 and Rip2, in flies
and mammalian cell line, respectively.
DISCUSSION
Here, we have focused onEscherichia coli toxin CNF1 as a proto-
type of bacterial effectors that activate the RhoGTPases (Akto-
ries et al., 2000; Lemonnier et al., 2007) and have demonstrated
that this toxin is sufficient to induce an immune response in the
absence of other microbial-derived innate immune agonists.
Using Drosophila as a genetically tractable system, we haveImmunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc. 543
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Figure 5. Modified Rac2 Interacts with the Innate Immune Adaptor IMD to Induce AMPs
(A) Immunofluorescence of S2 cells transfected with mRFP-Rac2L61 or Rac2N17 (red) and colocalization with endogenous IMD (green) determined by antibody
staining 16 hr after transfection. Nuclei is shown in blue (DAPI).
(B) IMD interaction with Rac2 was determined by Biotin-Streptavidin based pull-down of biotinylated Rac2 from BioeaseRac2L61 and BioeaseRac2N17 stable S2
cells. BioeaseLacZ acted as a negative control. Two percent of total cell lysate before streptavidin purification was loaded on the gel (Input) or proteins eluted after
streptavidin pull-down purification (PD). Endogenous IMD was detected by immunostaining. Transfection and pull-down efficiency for the two BioeaseRac2
mutants is shown by Streptavidin-HRP staining of the input and PD specimens, respectively.
(C) Binding of native GST-Rac2 or GST-Rac2 modified by CNF1 to IMD in S2 cell lysates was determined by immunoblotting. Densitometry of IMD normalized for
GST-Rac2 pull-down efficiency in three independent experiments (mean ± SD).
(D) In vivo AMPs response to CNF1 wasmeasured in pools of WT (black bars), imd1 (dark blue bars), and imdshadok (green bars) flies intoxicated with purified toxin
andmeasured at 6 hr.Drosomycin andDiptericin expression profiles were quantified byQRT-PCR in pools containing three ormore flies (mean ± SEMof six pools
from three independent experiments). *p < 0.05, **p < 0.01.
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Immunity
Effector-Triggered Immunity via Rac2 and IMDfound that this effector-triggered immune response is initiated
not by direct recognition of CNF1 but in response tomodification
and activation of a host protein, Rac2, which then engages
immune signaling pathways primarily via the innate immune
adaptor IMD. Extending these observations to mammalian cells,
we show that the immune response to CNF1 is conserved and
triggered by the engagement of Rip proteins by activated human
Rac2. The precise molecular mechanism of how the immune
response is activated by Rac2 will need to be further defined.
However, our observation that deletion of the CAAX-box, which
is necessary for membrane targeting of RhoGTPases, prevents
Rac2L61-induced AMPs leads us to propose that Rac2 functions
by stabilizing the interaction of signaling adaptors at such sites
and can therefore obviate the need for engagement of PRRs.
This possibility is further supported by data in mammals in which
it has been shown that membrane targeting of RIP2 by addition
of a myristolation sequence is sufficient to induce NF-kB activa-
tion and bypasses the requirement for the receptor NOD2
(Le´cine et al., 2007).
Reminiscent of effector-triggered immunity in plants, which
has been shown to be critical for host defense in resistant strains
(Dangl and Jones, 2001; Jones and Dangl, 2006), the immune
response to CNF1 is not simply a bystander of the virulence
activity but can confer upon the host resistance to infection.
Thus, this mechanism of pathogen surveillance provides an
example of how immunity in metazoans can be triggered inde-
pendently of MAMP recognition by PRRs. Importantly, this
effector-triggered immune response occurs when microbes
express so-called ‘virulence’ factors and hence is likely to be
induced specifically during infection with bacteria with patho-
genic potential.
A number of models have been suggested to explain how the
immune system specifically amplifies the response to pathogens
but not harmless commensals. As an example, one proposed
mechanism of sensing of virulent microbes is through the
NLRP3 inflammasome, which can be activated by pathogens
that express pore-forming toxins and cause membrane disrup-
tion (Freche et al., 2007; Gurcel et al., 2006; Mariathasan et al.,
2006). However, other studies attempting to identify how the
host senses and responds to the secretory apparatus and/or
effectors of bacteria have concluded that the responses are
mediated by noncanonical immune pathways (Auerbuch et al.,
2009; Bruno et al., 2009; Shin et al., 2008). Similarly, the response
to CNF1 described herein does not require NLRs, which are
absent from the innate immune arsenal of Drosophila, indicating
that indirect sensing of virulent microbes does not rely solely on
the inflammasome and can be mediated by other immune
pathways. Although we would draw comparisons between our
system and any other pathogen with caution, together these
studies point to the existence of an alternative, but currently
poorly defined, mechanism of immune activation that allows
the host to differentiate virulent from avirulent micro-organisms.(E) In vivo AMPs response to CNF1wasmeasured in pools ofWT, imdshadok, andM
Diptericin expression profiles were quantified by QRT-PCR in pools containing t
(F) In vivo bacterial loads inWT, Rac2D (left) or imd1 (right) flies infected with E. coli
are representative of two or more similar experiments.
(G) Survival or WT, imd1, or PGRP-LC+LE double-mutant flies (15–25 per group
a Gehan-Breslow-Wilcoxon Chi-squared test.Our data are more consistent with a second model of pathogen
recognition that suggests that the host responds to the associ-
ated cellular and tissue damage (Matzinger, 1994; Matzinger,
2002; Casadevall and Pirofski, 2003). These ideas have recently
been included in a more expansive framework of pathogen
versus nonpathogen discrimination that takes into consideration
theseandother features that are associated specificallywith viru-
lent microbes termed ‘‘Patterns of Pathogenesis’’ (Vance et al.,
2009). Our findings expand this framework to include very
specific perturbations of homeostasis caused when effectors
target critical signaling pathways or essential regulatory proteins.
Recent work has highlighted the complex strategies evolved
by microbes during the course of the host-pathogen dynamic
and indicate that not all bacterial effectors can be considered
as simple virulence factors that act solely to the detriment of
the host. Indeed, many pathogens have evolved bacterial effec-
tors that modify the host cell cytotoxicity (Shames and Finlay,
2010). Not only can effectors limit damage but previous work
has shown that they can also drive immune responses both
in vitro (Bruno et al., 2009) and in vivo (Gottar et al., 2006).
However, the in vivo consequences of the increased defense
reaction remain to be defined and, in most cases, it is assumed
to be part of the virulence strategy of the microbe or due to the
increased bacterial load. This contrast with the situation for
CNF1, whichwe show is sufficient to induce protective immunity.
This important distinction indicates that the response to CNF1
has similar consequences to the effector-triggered immunity
described in plants, in which it is well recognized to act to limit
microbial replication and protect a resistant host. Historically,
investigators in the plant field have referred to these sorts of
effectors as ‘‘avirulence’’ factors because, when expressed by
bacteria, they negatively impact the ability of a pathogen to infect
the host (Mansfield, 2009). However, it is now understood in the
plant system that such effectors are directly or indirectly recog-
nized by the host to initiate effector-triggered immunity and
hence by augmenting the immune response contribute to host
resistance to themicrobe. These observations do raise the ques-
tion as to why pathogens would retain such ‘‘avirulence’’ genes,
a point that has been debated by plant immunologists for years.
However, it is now clear from the work in plants that not all hosts
mount a response and responsiveness depends on whether
a host has the correct receptor. In a resistant host the effector
acts as an ‘‘avirulence gene,’’ whereas in hosts that lack the
receptor, the effector promotes virulence. Thus, it is a tradeoff
for the pathogen as the factor that allows it to infect one host
may also be the thing that prevents it effectively infecting
another. This variation in ability to respond to an effector may
only be apparent at a population/species level. Alternatively, in
the context of a complex metazoan such as flies or mammals,
it may be different in different tissues. Thus variation in resistance
and susceptibility due to a differential ability to mount an ETI
may explain the tropism of certain pathogens for certain tissuesyd88 flies intoxicated with purified toxin andmeasured at 6 hr.Drosomycin and
hree or more flies (data representative of two similar experiments).
J96 (white) or mutants lacking CNF1 (black). Mean ± range of c.f.u. per fly. Data
) infected with E. coli K12-CNF1 or E. coli K12 CNF1-C866S. *p < 0.05 using
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Figure 6. Modified Human Rac2 Interacts with the IMD-Related Molecules, Rip1 and Rip2
(A) Coimmunoprecipitation of myc-hRac2L61 or hRac2N17 with Flag-Rip1 or Rip2 expressed in HEK293T cells.
(B and C) Immunofluorescence showing cells co-transfected with a plasmid expressing Myc-tagged hRac2 mutants hRac2L61 or hRac2N17 and the Flag-Rip1 (B)
or Flag-Rip2 (C). Red, anti-Myc; green, anti-Flag antibodies; blue (DAPI), nuclei. The scale bar represents 10 mm.High-magnification images of indicated fields are
shown in inserts.
Immunity
Effector-Triggered Immunity via Rac2 and IMDand/or the variation in host susceptibility across the population,
both possibilities that will need to be further explored. The obser-
vation that species phylogenetically distant from plants also
monitor and respond to microbial effectors suggest that this is
a convergent evolutionary strategy for identifying and defending546 Immunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc.against virulent pathogens. Taken together these data define
a mechanism of effector-triggered immunity and show how it
can be a potentially important means by which metazoans
discriminate harmless microbes from those with pathogenic
potential and differentially respond to virulent microorganisms.
100
200
300
400
500
600
700
800
CNF1
Rac2N17
IL
-8
 (p
g/
m
l)
1
2
3
4
5
6
7
I
L
-
8
 
ex
pr
es
si
on
 
(fo
ld
 in
du
ct
io
n)
0
20
40
60
IL-6 TNF-α
0
10
20
30
40
50
60 hRac2L61hRac2N17
D E
A
0
5
10
15
20
25
6hrs
Time
Control
HIA CNF1
CNF1 **
C
2
6
10
14
RNAi:
RNAi:
  NT
 RIP1
 RICK/RIP2 - - - + +
- - + - +
- + - - +
Myc-hRac2N17 - - - - -
- - - + +
- - + - +
- + - - +
+ + + + +
Myc-hRac2L61 + + + + +
Anti -RIP1
Anti -RICK/RIP2
Anti -Myc
Anti -Actin
RIP1Non
targeting
MockRNAi:
0.2
0.4
0.6
0.8
1
1.2
F
HG
hRac2L61
hRac2N17
hRac2L61
hRac2N17
-
-
+ +
+ +-
- CNF1
Rac2N17
-
-
+
+-
-
I
L
-
8
 
ex
pr
es
si
on
- CS
RNAi: - - RIP1
+RIP2
CT
I
CNF1:
6
2
4
5
3
1
0
2
4
6
8
10
12
CN
F1
CS
CN
F1
CT
I
L
-
8
 e
xp
re
ss
io
n
(fo
ld
 in
du
ct
io
n)
LP
S
B
-
+
24hrs
IL-1βIL-8
I
L
-
8
 e
xp
re
ss
io
n
N
F-
κ
B
 in
du
ct
io
n 
(R
LU
)
CT
Mo
ck
Ra
c2
 N
17
Ra
c2
 W
T
Ra
c2
 L6
1
N
F-
κ
B
 in
du
ct
io
n 
RIP2 RIP1
+RIP2
RIP1Non
targeting
RIP2 RIP1
+RIP2
- - - - -
N
F-
κ
B
 in
du
ct
io
n 
(R
LU
)
C
yt
ok
in
e
ex
pr
es
si
on
 
(n
or
m
al
iz
ed
 to
 c
on
tro
l)
+
+
Figure 7. CNF1 Induces an Immune Response after Modification of Human Rac2 that Induces Signaling via IMD-Related Molecules, Rip1
and Rip2
(A) NF-kB activation in control HEK293T cells (white bars), cells exposed to purified heat-inactivated CNF1 (gray bars) and CNF1 (black bars) (mean ± SD).
(B) IL-8 induction by CNF1-C866S (CS) or CNF1 (CT) intoxication or by the addition of 100 ng/ml LPS.
(C) CNF1 induction of IL-8, after 24 hr of intoxication, in the presence or absence hRac2N17 that functions as a dominant-negative inhibitor of Rac.
(D and E) NF-kB induction (D) and cytokine expression (E) triggered by hRac2 mutants, hRac2L61, or hRac2N17 expression in HEK293T cells (mean ± SEM, n = 3).
(F–H) Rip1 or Rip2 or a nontargeting (NT) siRNA were transfected in HEK293T cells 72 hr as indicated.
(F) The endogenous Rip1 and Rip2 immunoblot shows siRNA efficiency and specificity of the siRNA. Anti-Myc staining demonstrates levels of transfection of
Myc-hRac2 mutants. Actin staining was used as a loading control.
(G) Quantification of hRac2L61 induced NF-kB activation in Rip1 and Rip2 knocked down cells. NF-kB Firefly-luciferase in total cellular lysates was measured and
transfection efficiency of the reporter was normalized with Renilla activity. Results were expressed as the percentage of hRac2L61-expressing cells, mock
transfected with siRNA.
(H) IL-8 gene expression monitored by QRT-PCR after siRNAi transfection of HEK293T cells expressingMyc-hRac2mutants as described above. Actin was used
as housekeeping gene and internal control and data expressed normalized to untreated cells. Data are from cells grown in triplicate wells and representative of
three independent experiments.
(I) CNF1 induction of IL-8, after 24 hr of intoxication, in the presence or absence RIP1 and RIP2 knockdown. All data are shown as the mean ± SD of biological
triplicates and representative of three independent experiments unless otherwise stated; *p < 0.05, **p < 0.01.
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Standard methods and methods pertaining to the mammalian work can be
found in the Supplemental Information.
Fly Infections, Intoxication, and Survival Experiments
FordetailsofflystockspleaseseeSupplemental ExperimentalProcedures.UAS-
CNF1 lines were maintained at 18C and crossed to Pw+mC Tub-Gal80ts2;hsp-Gal4drivers (gift of D. Ferrandon) for induction of toxin expression by heat shock
(30min 37C, 30min 25C, 30min 37C, and 16hr incubation 25C). For CNF1CT
and CNF1CS flies’ AMPs profile analysis, a single-fly qRT-PCR was performed.
Expression of the transgenewas confirmed by PCR. Three ormore independent
lines with different insertions were analyzed.
E. coli J96 or J96-DCNF1 were grown in LB overnight at 37C and diluted
one-fourth and subcultured up to OD600 = 0.7. Cultures were centrifuged
(3000 rpm, 5 min) and the supernatant was removed. A tungsten needle wasImmunity 35, 536–549, October 28, 2011 ª2011 Elsevier Inc. 547
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Effector-Triggered Immunity via Rac2 and IMDdipped into the bacterial pellet and used to prick 15–25 adult male flies that had
been placed on sterile food for 24 hr previously. Pools of three flies were
homogenized in PBS and dilutions plated and grown on Streptomycin plates
overnight. Bacterial loads were determined by colony counting. For some
survival experiments, E. coli K12 were transformed with pQE30-His-CNF1 or
pQE30-His-CNF1-C866S. Bacteria were grown overnight at 37C in LB sup-
plemented with ampicillin (100 mg/ml) and IPTG (10 mM). Bacteria were then
diluted 1/100 and subcultured up to OD600 = 0.8 and then IPTG (1 mM) was
added for 16 hr at 30C. A tungsten needle was dipped into the bacterial pellet
and used to prick 15–25 adult flies. Flies were then left in a sterile sucrose 5%
supplemented with (1 mM) IPTG and mortality was monitored for 24 hr. Flies
were intoxicated either by microinjection with 65 nl of 105 M recombinant
purified CNF1 toxin with Nanoject microinjector or by placing in vials contain-
ing a sucrose-based solution (5% sucrose, 10 mM Tris [pH 7.4]) containing
3.5 mg/ml of purified recombinant CNF1 toxin or the catalytically inactive
CNF1 mutant C866S. Control flies were added to vials containing only
sucrose. After 6 hr flies were lyzed and processed for Q-RT-PCR. Three or
more pools of three to five age-matched flies (males only) from WT, Rac2D,
imd1, or imdshadok were used.
RNA Interference and Epistasis Analysis in Drosophila S2 Cells
For screening, S2 cells stably expressing BioeaseRac2L61 (S2BioeaseRac2L61) were
used as they demonstrated a reproducible 3-fold induction of AMPs after
CuSO4 induction (Figure S3). Double-stranded RNA were synthesized and
purified as described previously (Stuart et al., 2007). Primers were designed
using sequences from the Drosophila Research Screening Center (Table S1).
The efficacy of the RNAi collection used was confirmed with cells expressing
either PGRP-LC or Toll10b or stimulated with PGN (Figure S3). All RNAis were
functional, although Dif and Dorsal are known to be partially redundant in
this S2 system (Silverman et al., 2000). Cells were treated with RNAi 72 hr
prior induction of BioeaseRac2L61 expression for 16 hr, expression of both
Drosomycin and Diptericin was compared to CuSO4 induced cells treated
with a control nontargeting RNAi.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at
doi:10.1016/j.immuni.2011.08.015.
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